By Julia Karow

Human whole-genome sequencing
for the clinical market will require a new type of product that delivers less data than is currently provided for the research market, according to Complete Genomics CEO Cliff Reid.

Reid also said that a lack of data analysis and storage capabilities is currently the greatest barrier preventing the company from securing large deals with translational medicine institutions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.